All News
Filter News
Found 7,388 articles
-
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
11/3/2023
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC taking place November 1 - 5, 2023 at the San Diego Convention Center in San Diego, CA.
-
Ahead of the Inflation Reduction Act’s drug price negotiations, the regulator has approved Amgen’s biosimilar challenge to Johnson & Johnson’s Stelara—with an interchangeable designation to boot.
-
Organon Reports Results for the Third Quarter Ended September 30, 2023
11/2/2023
Organon announced its results for the third quarter ended September 30, 2023.
-
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis
11/2/2023
Gedeon Richter Plc. together with Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH announce that the European Commission has granted approval of a Type II Variation application for RYEQO® for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
-
Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting
11/2/2023
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced new HD data will be presented at the Huntington Study Group® Annual Meeting on November 2-4 in Phoenix, AZ.
-
Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
11/2/2023
Lilly defines New Products as select products launched since 2022, which currently consist of Jaypirca, Mounjaro and Omvoh.
-
AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)
11/2/2023
Amgen (NASDAQ:AMGN) today announced new data for KRYSTEXXA ® (pegloticase) showing a decrease in blood pressure during treatment of adults living with chronic gout refractory to oral urate-lowering treatment − uncontrolled gout − both with and without chronic kidney disease (CKD).
-
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
11/2/2023
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, today reported financial results for the quarterly period ended September 30, 2023 and provided business highlights.
-
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
11/1/2023
Organon and Sempre Health announced a strategic partnership designed to motivate eligible patients to refill their prescriptions on time and improve adherence through an innovative pricing program that offers personalized support.
-
UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
11/1/2023
UCB announced that it will be presenting results from across its portfolio in generalized myasthenia gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting and the Myasthenia Gravis Association of America Scientific Session taking place November 1-4, 2023.
-
UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry
11/1/2023
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced the publication of efficacy and safety findings from the phase 3 Risperidone Subcutaneous Extended-Release study in The Lancet Psychiatry.
-
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
11/1/2023
Revance Therapeutics, Inc. (RVNC) today announced that the company will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the close of market.
-
AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO
11/1/2023
Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, following the recent acquisition of Horizon Therapeutics.
-
NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters
10/31/2023
UCB, a global biopharmaceutical company, announced that Epilepsy & Behavior published a post hoc analysis from the Phase 3 open-label extension study of NAYZILAM.
-
Amgen Reports Third Quarter 2023 Financial Results
10/31/2023
Amgen announced financial results for the third quarter of 2023.
-
FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases
10/31/2023
Today, the U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases.
-
Pfizer Reports Third-Quarter 2023 Results
10/31/2023
Pfizer Inc. reported financial results for the third quarter of 2023. The company reaffirms its 2023 revenue guidance range of $58.0 to $61.0 billion and its outlook for Adjusted diluted EPS of $1.45 to $1.65 provided on October 13, 2023.
-
Stevanato Group Reports Third Quarter 2023 Financial Results
10/31/2023
Stevanato Group S.p.A. announced its financial results for the third quarter of 2023.
-
AnHeart Therapeutics Announces Exclusive License Agreement With Nippon Kayaku for Taletrectinib in Japan
10/30/2023
AnHeart Therapeutics today announced it has entered into an exclusive license agreement with Nippon Kayaku Co., Ltd (“Nippon Kayaku”) to market and distribute AnHeart’s lead investigational therapy, taletrectinib, in Japan.
-
Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India
10/27/2023
Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with Intas Pharmaceuticals Limited ("Intas") for the development and commercialisation in Europe and India for several indications including ES-SCLC, and specific formulation of HANSIZHUANG (serplulimab injection), Henlius' novel anti-PD-1 mAb.